Skip to main content
Thomas Devlin, MD, Neurology, Chattanooga, TN

ThomasGDevlinMDPhD

Neurology Chattanooga, TN

Sleep Medicine, Vascular Neurology, Neurocritical Care

Assistant Professor, Clinical Education-Chattanooga, University of Tennessee Health Science Center College of Medicine

Dr. Devlin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Devlin's full profile

Already have an account?

  • Office

    721 Glenwood Dr
    Ste 467
    Chattanooga, TN 37404
    Phone+1 423-698-3423
    Fax+1 423-698-1380

Summary

  • Dr. Thomas Devlin, MD, PhD., is a neurologist practicing in Chattanooga, TN. He serves the local community in a number of positions that include Director of the National Stroke Prevention Training Center, Chairman of the Department of Neurology at the University Of Tennessee College Of Medicine, and Executive Director of Chattanooga Network for Stroke. As well, Dr. Thomas Devlin, MD, PhD., is active in many national and international health organizations. He is a National Steering Committee Member for Merci Registry Clinical Trials and the International Committee Chairman for New Technology Development for Brainsgate, LLC.

    A popular speaker and presenter, Dr. Thomas Devlin, MD, PhD., has lectured at events such as the Regional Nurses and Stroke Team Meeting in Orlando, Florida. Notably, Dr. Thomas Devlin, MD., PhD., was chosen to present his work to President George W. Bush at the Regional Stroke Center at Erlanger Hospital in 2007.

    Dr. Thomas Devlin, MD., PhD., has dedicated his career to medicine. He has authored dozens of publications on stroke and is considered one of the nation’s leading experts on neurological disorders. In 2014, Dr. Thomas Devlin, MD. PhD., was bestowed the Outstanding Physician Award from Erlanger Hospital. In 2010, along with Dr. Peter Hunt, Dr. Thomas Devlin, MD, PhD, was formerly recognized by Brainsgate as part of a two physician team to carry out the first successful human implantation of the Sphenopalantine Gangion Stimulator for Acute Ischemic Stroke.

    Dr. Thomas Devlin, MD. PhD., is Board Certified by the American Board of Sleep Medicine and the American Board of Neurology and Psychiatry.

Education & Training

  • University of Virginia Medical Center
    University of Virginia Medical CenterFellowship, Neurocritical Care, 1995 - 1996
  • Duke University Hospital
    Duke University HospitalResidency, Neurology, 1992 - 1995
  • Baylor College of Medicine
    Baylor College of MedicineClass of 1991
  • University of Connecticut Health Science Center
    University of Connecticut Health Science CenterPh.D, Neuroscience, 1984 - 1990

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 1996 - 2026
  • NE State Medical License
    NE State Medical License 2020 - 2026
  • NY State Medical License
    NY State Medical License 2020 - 2026
  • OH State Medical License
    OH State Medical License 2020 - 2026
  • FL State Medical License
    FL State Medical License 2020 - 2025
  • IN State Medical License
    IN State Medical License 2020 - 2025
  • KY State Medical License
    KY State Medical License 2021 - 2025
  • American Board of Psychiatry and Neurology Neurology
  • American Board of Psychiatry and Neurology Vascular Neurology
  • AOA Board of Neurology and Psychiatry Sleep Medicine (CAQ)
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Large Real-World, Multi-Center Study Demonstrates Viz.ai Platform Saves Critical Minutes in Stroke Care
    Large Real-World, Multi-Center Study Demonstrates Viz.ai Platform Saves Critical Minutes in Stroke CareFebruary 8th, 2023
  • Early Treatment via Mobile Stroke Units Yields Better Outcomes vs. ‘Drip and Ship’
    Early Treatment via Mobile Stroke Units Yields Better Outcomes vs. ‘Drip and Ship’August 5th, 2021
  • Lumosa Therapeutics Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke
    Lumosa Therapeutics Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic StrokeAugust 3rd, 2021
  • Join now to see all